Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Retifanlimab (retifanlimab-dlwr; ZYNYZ) is a programmed cell death 1 receptor-blocking antibody that is being developed by Incyte Corporation for the treatment of solid tumours, both as monotherapy and in combination with other agents. Retifanlimab recently received accelerated approval for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. This article summarizes the milestones in the development of retifanlimab leading to this first approval for Merkel cell carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40265-023-01884-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polyomavirus Antibodies for Merkel Cell Carcinoma Recurrence Detection.
JAMA Dermatol
September 2025
Department of Dermatology, University of Washington, Seattle.
Importance: Merkel cell carcinoma (MCC) is typically caused by the Merkel cell polyomavirus (MCPyV) and recurs in 40% of patients. Half of patients with MCC produce antibodies to MCPyV oncoproteins, the titers of which rise with disease recurrence and fall after successful treatment.
Objective: To assess the utility of MCPyV oncoprotein antibodies for early detection of first recurrence of MCC in a real-world clinical setting.
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis.
Immunotherapy
September 2025
Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
Currently, the first-line treatment of non-metastatic Merkel cell carcinoma (MCC) is complete resection. In case of unresectable or metastatic MCC, immune checkpoint inhibitor (ICI) therapy with avelumab (or in the US also pembrolizumab or retifanlimab) is indicated. We report on a patient with a primary, non-metastatic MCC on the left eyelid and amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDFIncidental Histologic Findings During Mohs Micrographic Surgery: A Systematic Review.
Dermatol Surg
September 2025
HCA Florida Orange Park Hospital, Orange Park, Florida.
Background: Mohs micrographic surgery (MMS) allows for precise excision of skin cancers with intraoperative histologic margin assessment. Incidental findings-unexpected histopathologic features unrelated to the primary lesion-are occasionally discovered but scantily characterized in the literature.
Objective: To systematically review published cases of incidental histologic findings identified during MMS, with attention to their frequency, clinical implications, and management.
Viral oncogenesis and immune remodeling: Decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers.
Biomed Pharmacother
September 2025
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address:
Various viruses are widely recognized as key contributors to the development of numerous hematological malignancies and solid tumors. It is estimated that virus-associated cancers account for approximately 1.5 million new cases globally each year.
View Article and Find Full Text PDFImpact of Prior Malignancies on Survival of Patients With Merkel Cell Carcinoma.
Dermatol Surg
September 2025
Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.